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SUMMARY
Background
Proton pump inhibitors (PPIs) are the preferred agents for the prevention
of aspirin-associated upper gastrointestinal bleeding (UGIB). Data are lim-
ited to determine whether PPIs are being used to reduce UGIB risk.
Aim
To evaluate the implementation of PPI treatment to reduce the GI risk in
two cardiology centres from Europe and the United States.
Methods
A retrospective cross-sectional study was carried out at the University of
Michigan and University Hospital-Zaragoza in 429 consecutive patients
hospitalized for percutaneous coronary intervention (PCI) on dual anti-
platelet therapy.
Results
Admission for PPI co-therapy was similar (34% vs. 30%) in both centres.
At discharge, the proportion of high-risk patients receiving PPI therapy in
the Spanish centre (75.4%) was higher than their American peers (55.6%)
(OR: 2.5; 95% CI; 1.3–4.7). No differences in PPI prescription rates were
found among Spanish patients with ⁄ without GI risk factors. The opportu-
nity to initiate PPI co-therapy in high-risk patients was missed in 81.8%
(36 ⁄ 44) of those not on PPI at admission in US patients vs. 24.1% (19 ⁄ 79)
(P < 0.0001) in Spanish patients.
Conclusions
There are important differences concerning PPI prescription and risk strati-
fication in the two centres when managing PCI patients. Efforts to stratify
risks and utilize appropriate strategies for UGIB prophylaxis in high-risk
patients are warranted.
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INTRODUCTION
Dual antiplatelet therapy with aspirin (ASA) in addition
to clopidogrel (CLP) reduces recurrent cardiovascular
events in acute coronary syndrome among patients trea-
ted medically or with percutaneous coronary intervention
(PCI).1, 2 It is also well established that ASA is associated
with a twofold increased risk of upper gastrointestinal
bleeding (UGIB), which is further increased when com-
bined with CLP therapy. The presence of independent
ulcer risk factors that include age >70, previous ulcer his-
tory (complicated > uncomplicated), Helicobacter Pylori
infection and concomitant therapy with anticoagulants,
NSAIDs or steroids are well established.3–7
A recent consensus document published by the
American College of Gastroenterology,8 the American
College of Cardiology Foundation and the American
Heart Association concludes that proton pump inhibi-
tors (PPI) should be considered in any person with risk
factors for gastrointestinal bleeding receiving antiplatelet
therapy.9 After PCI therapy, patients are prescribed dual
antiplatelet therapy with ASA and CLP, putting these
patients at GI risk, especially among those patients with
additional risk factors. Therefore, physicians must evalu-
ate the GI risk profile and adopt prevention therapies
in an attempt to reduce GI complications.10, 11 The
consensus document was motivated, in part, by the
hypothesis that non-GI physicians did not systematically
consider UGIB risk or respond with appropriate gastro-
protective strategies.
Although some concerns have been raised that the co-
administration of a PPI with CLP could pose a risk of
drug interaction via cytochrome P450 2C19,11, 12 and
therefore have the potential to increase the risk of CV
events,11, 13 the recommendations of the panel have not
been changed for reasons of lack of firm evidence of a
clinically important interaction leading to worsened CV
outcomes. However, regulatory agencies have proposed
warnings that careful evaluations of the CV and GI risks
should be undertaken in the individual patient.14, 15 Fur-
thermore, as more recent data suggest that the potential
interaction between these two drugs may have no clinical
impact on CV events,16 and as other therapeutic alterna-
tives such as misoprostol, H2-blockers or H. pylori eradi-
cation have still poor evidence of being effective as
preventive strategies,10 PPI co-therapy still remains the
main prevention therapy for those at risk taking antiplat-
elet therapy.
No study has evaluated whether PPIs are being pre-
scribed to reduce UGIB risk in at-risk patients on dual
antiplatelet therapy after PCI. We also sought to deter-
mine whether there are different prescription habits
between centres in different countries.
METHODS
Study design and setting
The study was designed as a retrospective cross-sectional
study of medical records at the University Hospital Loz-
ano Blesa in Zaragoza (Spain) and at the University of
Michigan Medical School (US). Patients admitted to the
hospital for PCI between January 2007 and December
2007 were eligible for inclusion. Data were obtained from
charts after discharge and included basic demographic
information, date of hospitalization and discharge, cause
of hospitalization, presence of co-morbidities, cardiovas-
cular events and GI bleeding during hospitalization.
Medical treatment received by patients before and during
hospitalization and prescription issued at discharge were
also recorded. The ethics committee in both centres
reviewed and approved the study protocol.
Patients





All patients included in the study were hospitalized to
undergo PCI from coronary heart disease (acute myocar-
dial infarction, unstable or stable angina). Risk factors
considered for UGIB were age >70, ulcer history and
concomitant therapy with anticoagulants, NSAIDs or ste-
roids.3, 4, 6 Patients with ‡1 risk factor (in addition to
dual antiplatelet therapy) were defined as ‘high-risk’
(HR) for UGIB. The proportion of patients at discharged
on PPI therapy was calculated and stratified by GI bleed-
ing risk. All patients received low-dose ASA therapy
(75 or 162 mg ⁄ day) in addition to CLP 75 mg ⁄ day. A
loading dose (300 mg of CLP) was administered as
appropriate.
Statistics
We assumed that the average rate of Spanish patients on
PPI at discharge was 60%, and that of the US patients,
40%. Therefore, we planned to enrol approximately 140
patients in each study group who could be evaluated for
the study to have 90% power to detect a significant dif-
ference in the rates of patients discharged on PPI
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between the two centres with a two-tailed significance
level of 0.005 or less. Statistical differences and odds
ratios were calculated using Chi-square test for discrete
variables and t-tests for continuous variables (expressed
as mean values and standard deviation). All statistical
tests were performed with the use of SPSS software (SPSS
v14, Chicago, IL, USA).
RESULTS
Table 1 defines the patient demographics and clinical
characteristics of the study population. Patients from the
Spanish centre were older than those from the US, trans-
lating into a higher proportion of patients at high GI risk
in the Spanish population. However, the Americans had
significantly more cardiovascular co-morbidities (hyper-
tension, hypercholesterolemia and diabetes). American
patients were also more frequently on cardiovascular
medications on admission. There were no differences
regarding GI ulcer history in the Americans. PPI treat-
ment at admission was also similar (Table 1). The two
most frequent reasons for PPI at admission among
Americans were gastro-oesophageal reflux disease in
22.6% (n = 45) and past history of GI bleeding in 4.5%
(n = 9). No reasons for PPI use were recorded among
most Spanish patients in the admission documents and
therefore these data are not reported here for the Spanish
cohort.
Of the Spanish patients not on PPI before admission
[70% of the cohort (n = 161)], 49.7% (n = 80) had 1 or
more GI risk factors and 50.3% (n = 81) were low-risk
patients. Similarly, for the Americans not on PPI before
admission [68% of the cohort (n = 131)], 34.4% (n = 45)
were HR patients and 65.6% (n = 86) were low-risk
patients.
During hospitalization (Table 2), 93% (n = 185) of the
American and 96.7% (n = 223) of the Spanish patients
had a coronary stent placed. Two patients died during
hospitalization – one of complications with anoxic brain
Table 1 | Baseline characteris-




(n = 199) P-value
Age, mean (s.d.) 67.4 (8.9) 62.5 (11.7) <0.0001
Male gender 193 (83.9) 154 (77.4) 0.0877
Age >70 95 (41.3) 49 (24.6) 0.0003
NSAID use 15 (6.5) 17 (8.5) 0.4308
Ulcer history 13 (5.7) 17 (8.5) 0.2570
Steroids (>10 mg daily) use 7 (3.0) 5 (2.5) 0.7529
Oral anticoagulants 11 (4.8) 14 (7.0) 0.3318
High-risk GI patients 116 (50.4) 82 (41.2) 0.0566
Hypertension 126 (54.8) 147 (73.9) <0.0001
Hypercholesterolemia 133 (57.8) 151 (75.9) 0.0001
Diabetes mellitus 60 (26.1) 72 (36.2) 0.0238
Previous CABG 5 (2.2) 38 (19.1) <0.0001
Previous stroke or transient
ischaemic attack
14 (6.1) 22 (11.0) 0.0677
At admission on
No antiplatelet agent 120 (52.2) 64 (32.2) <0.0001
ASA alone 61 (26.5) 88 (44.2) 0.0001
Clopidogrel alone 3(1.3) 4 (2) 0.5674
ASA and clopidogrel 45 (19.6) 43 (21.6) 0.6090
PPI 69 (30) 68 (34.2) 0.3522
Statins 89 (38.7) 114 (57.3) 0.0001
Values are expressed as n (%), unless specified.
CABG, coronary artery bypass graft; PPI, proton pump inhibitor.
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injury and another because of septic shock in the
Spanish centre, and two patients in the US due to
ventricular fibrillation and anoxic brain injury. The
proportion of patients who received PPI therapy during
hospitalizations was high and increased when compared
with those receiving PPI at admission, especially in the
Spanish cohort in both high- and low-risk GI patients,
whereas that proportion was much lower in the US
patients (Table 2). Three patients (two from Spain and
one from the US centre) had an in-hospital GI bleeding
after the interventional procedure (the three were on a
PPI and two were HR patients).
At discharge (Table 3), 419 (98.5%) of the 425
patients of entire population were on dual antiplatelet
therapy; two of 197 (1%) of the US patients and none of
the Spanish were on aspirin alone. Overall, in the Span-
ish centre, 171 ⁄ 228 (75.0%) patients were prescribed PPI
therapy at discharge vs. 81 ⁄ 197 (41.1%) patients in the
US (OR: 4.3; 95% CI: 2.8, 6.6; P < 0.0001). When
patients discharged from hospital were stratified accord-
ing to the presence of risk factors (Figure 1), PPI rates
were similar in patients with no risk factors (83 ⁄ 114;
73%) or one or more risk factors (86 ⁄ 114; 75.4%) in the
Spanish centre (P = 0.679), whereas the Americans with
no risk factors (36 ⁄ 116; 31.0%) differed from the HR
cases (45 ⁄ 81; 55.6%) (P = 0.0006).
Overall, HR American patients were more likely than
low-risk patients to be discharged on a PPI (OR = 2.8,
95% CI: 1.5–5.2, P = 0.0007). In both centres, the pro-
portion of PPI therapy increased further for those
patients with one or more risk factors (Figure 2). Table 4
also includes PPI prescription rates according to individ-
ual risk factors. Figures were always higher for the Span-
ish cohort. Considering HR patients not on PPI at
admission (80 of 116 among the Spanish cohort and 45
of 82 in the US cohort; of the two Spanish patients who
died during hospitalization, both were HR and one was
on PPI, whereas of the two Americans, one was HR and






(n = 199) P-value
Stent placement 224 (97.4) 185 (93.0) 0.0307
High-risk GI patients on PPI 87 ⁄ 116 (75.0) 37 ⁄82 (45.1) <0.0001
Low-risk GI patients on PPI 80 ⁄ 114 (70.1) 31 ⁄ 117 (26.5) <0.0001
In-hospital GI bleeding complications 2 (0.9) 1 (0.5) 0.7724
In-hospital death 2 (0.9) 2 (1.0) 0.9150
Length of hospitalization (days),
mean (s.d.)
6.8 (6.78) 3.2 (4.52) <0.0001
Values are expressed as n (%), unless specified.
GI, gastrointestinal; PPI, proton pump inhibitor.





(n = 197) P-value
Dual antiplatelet agents 223 (97.8) 196 (99.5) 0.1385
PPI 171 (75.0) 82 (41.2) <0.0001
High-risk GI patients
on PPI at discharge
86 ⁄ 114 (75.4) 45 ⁄81 (55.6) 0.0037
Low-risk GI patients
on PPI at discharge
83 ⁄ 114 (72.8) 36 ⁄ 116 (31.0) <0.0001
Bleeding in follow-up 3 (1.3) 4 (2.0) 0.5692
Values are expressed as n (%).
GI, gastrointestinal; PPI, proton pump inhibitor.
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not on PPI), the opportunity to initiate PPI co-therapy
following PCI and treatment with dual antiplatelet ther-
apy at discharge in this population was missed in 81.8%
(36 ⁄ 44) of the US patients. In the Spanish cohort, the
proportion was 24.1% (19 ⁄ 79) (P < 0.001), but seven
additional HR patients on PPI at admission were
discharged with no PPI, which means that in this cohort,
the overall opportunity was missed in 22.8% (26 ⁄ 114) of
patients.
DISCUSSION
According to current recommendations, patients at risk
for UGIB receiving dual antiplatelet therapy with ASA
and CLP should receive PPI co-therapy.8, 11, 17–19 Our
study shows that the probability of receiving PPI ther-
apy at hospital discharge varied significantly among the
two centres studied. We found that the proportion of
patients being prescribed PPI at discharge in the
Spanish centre was significantly higher than that
observed in patients from the US. The data should be
of interest, as no study has reported transatlantic pre-
scription habits in this type of patients.20–22 As the
study collected information from patients records before
concerns on the potential interaction of PPI with CLP
were raised, the data reflect the awareness among the
cardiologists in those centres on the necessity for risk
assessment and response with co-prescription to reduce
the risk of UGIB. We suspect that the more recent
developments concerning the potential interaction
of CLP with PPI may have significantly reduced
co-prescription rates.
It remains unclear whether the data observed in
these two centres reflect prescription habits among all
cardiologists in other practice settings in their respective
countries. However, we suggest that it may well be the
case, as data on GI bleeding and drug use, for example,
from at least one of the centres (Zaragoza), have
been often reproduced in other centres of the same
country.23, 24
From the data reported here, it can be concluded that
cardiologists in the Spanish centre are more concerned
about the UGIB risk associated with dual antiplatelet
therapy than their American peers, even before the rec-
ommendations of the consensus document were pub-
lished.5 However, the data show that the PPI
prescription observed in the Spanish centre was not
guided by the assessment of the underlying UGI risk fac-
tors, as the prescription of PPI is essentially independent
of the presence of and the number of GI risk factors. On
the contrary, this was the case in the US centre, but the
gap of risk reducing co-therapy in high patients was
much larger than in Spain, which reduces the overall
clinical impact, and still, a significant proportion of the
group of HR patients for UGIB were not started on PPI
in both centres.
The reasons for the differences in PPI prescription rates
found in both centres, which could be generalized to other
centres in the respective countries, remain unclear. Differ-




















Figure 1 | Proton pump inhibitor prescription at

















No risk factors 1 risk factor >1 risk factor
USA
Spain
P < 0.0001 P = 0.0185 P = 0.0364
Figure 2 | Proton pump inhibitor therapy at discharge in
relation to GI risk factors.
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concerns, although the fact that medications are widely
subsidized by the health system in the European centre
may facilitate prescription to patients, especially if CV
safety is not of concern. More likely the differences may be
due to different perceptions on the intrinsic GI risk of an-
tiplatelet therapies, as PPIs are widely prescribed across
Spain to patients receiving potential gastro-toxic agents
such as NSAIDs.25 In any case, the lack of selectivity of
PPI prescription in the Spanish centre and the wide gap of
that in at-risk patients in the American one show that
there is a clear opportunity to better educate physicians
better on the importance of gastroprotection in this group
of patients and develop better educational programmes to
disseminate the appropriate guidelines towards the goal of
reducing UGIB.
The strengths of our study include the use of well-
defined risk factors and end points as well as the use of
structured data collection from hospital medical records
(electronic in US and manual review of charts in Spain),
which contained all the data required for the study.
There are also limitations of our study. The first is that
our analysis was based on medical and prescription
records. A systematic assessment of medication compli-
ance was not possible due to the study design. While this
is an important consideration, it should be noted that
the purpose of this study was to describe prescription
patterns of physicians in two different countries. Another
weakness is that GI bleeding risk may have been
considered by the prescribers, but other aspects in the
decision-making process, including cost and insurance
reimbursement policies, are not or may not be
documented and, however, have a clear impact on the
observed differences.
In summary, our data provide evidence that GI risk
reduction strategies are not considered routinely for
at-risk patients on dual antiplatelet agents and that
co-therapy to reduce risk varies widely across centres
from two different countries. Our study also demon-
strates that prescription may not always be based on
proper assessment of risk factors. We conclude that
future efforts be implemented to improve the rates of GI
risk assessment and of prevention strategies among the
HR population as well as future studies to assess the GI
and CV impact of these strategies.
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(n = 197) P-value
No risk factors 83 ⁄ 114 (72.8) 36 ⁄ 116 (31.0) <0.0001
1 Risk factor 68 ⁄94 (72.3) 34 ⁄63 (54.0) 0.0185
>1 Risk factor 18 ⁄20 (90.0) 11 ⁄ 18 (61.1) 0.0364
Age ‡70 years old 71 ⁄93 (76.3) 28 ⁄49 (57.1) NS
Previous history of peptic ulcer disease 11 ⁄ 13 (84.6) 12 ⁄ 17 (70.6) NS
Concurrent warfarin use 9 ⁄ 11 (81.8) 7 ⁄ 14 (50) NS
Concurrent use of corticosteroids ‡10 mg daily 7 ⁄7 (100.0) 4 ⁄ 5 (80) NS
Concurrent use of non-aspirin NSAIDs 13 ⁄ 15 (86.7) 7 ⁄ 17 (41.2) 0.0328
Values are expressed as n (%).
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